Aprepitant versus dexamethasone for delayed emesis: What is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron?

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)2185-2186
Number of pages2
JournalJournal of Clinical Oncology
Volume32
Issue number20
DOIs
Publication statusPublished - Jul 10 2014

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{3f0a9668545044a2b4ad11fdbbe42ab8,
title = "Aprepitant versus dexamethasone for delayed emesis: What is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron?",
author = "Luigi Celio and {De Braud}, Filippo and Matti Aapro",
year = "2014",
month = "7",
day = "10",
doi = "10.1200/JCO.2014.55.4352",
language = "English",
volume = "32",
pages = "2185--2186",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "20",

}

TY - JOUR

T1 - Aprepitant versus dexamethasone for delayed emesis

T2 - What is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron?

AU - Celio, Luigi

AU - De Braud, Filippo

AU - Aapro, Matti

PY - 2014/7/10

Y1 - 2014/7/10

UR - http://www.scopus.com/inward/record.url?scp=84905822381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905822381&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.55.4352

DO - 10.1200/JCO.2014.55.4352

M3 - Article

C2 - 24912893

AN - SCOPUS:84905822381

VL - 32

SP - 2185

EP - 2186

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 20

ER -